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Immunotherapy for cancer has shown increasing success and there is ample evidence
to expect that progress gleaned in immune targeting of adult cancers can be trans-
lated to pediatric oncology. This manuscript reviews principles that guide selection of
targets for immunotherapy of cancer, emphasizing the similarities and distinctions between
oncogene-inhibition targets and immune targets. It follows with a detailed review of mole-
cules expressed by pediatric tumors that are already under study as immune targets or are
good candidates for future studies of immune targeting. Distinctions are made between
cell surface antigens that can be targeted in an MHC independent manner using antibod-
ies, antibody derivatives, or chimeric antigen receptors versus intracellular antigens which
must be targeted withMHC restrictedT cell therapies. Among themost advanced immune
targets for childhood cancer are CD19 and CD22 on hematologic malignancies, GD2 on
solid tumors, and NY-ESO-1 expressed by amajority of synovial sarcomas, but several other
molecules reviewed here also have properties which suggest that they too could serve as
effective targets for immunotherapy of childhood cancer.
Keywords: immunotherapy, tumor antigens, pediatric cancer, adoptive immunotherapy, chimeric antigen receptor,
antibody therapy, tumor immunity
PRINCIPLES GUIDING SELECTION OF TARGETS FOR
IMMUNOTHERAPY OF CANCER
Improved outcomes for childhood cancer rests upon the devel-
opment of new, targeted therapies to kill tumor cells. Much work
has focused on targeting oncogenes mediating growth pathways
to which the tumor has become “addicted” (Diehl et al., 2007;
Sharma and Settleman, 2007; Weinstein and Joe, 2008). This
strategy has yielded some impressive results, including the devel-
opment of ABL inhibitors for chronic myeloid leukemia (Cortes
et al., 2011), KIT inhibitors for gastrointestinal stromal tumor,
and BRAF inhibitors for melanoma (Dhomen and Marais, 2009;
Ribas and Flaherty, 2011). However, not uncommonly, onco-
gene inhibitors fail to mediate signiﬁcant antitumor effects due
to redundant growth/survival pathways that bypass the targeted
pathway (e.g., FLT3 inhibitors in acute myeloid leukemia, EGF
inhibitors in lung cancer; Diehl et al., 2007; Christoffersen et al.,
2009; Normanno et al., 2009; Siena et al., 2009). For this rea-
son, oncogene-inhibition has not yet assumed a major role in the
treatment of pediatric cancers.
An alternative paradigm for targeted cancer therapy utilizes
immune based therapies where the principles underlying target
selection differ in some ways from those driving selection of
oncogene-inhibition targets (Cheever et al., 2009). Most notably,
while oncogene-inhibition targets must mediate non-redundant
growth/survival pathways, immune targets need not play a signif-
icant role in the life or death of the cancer cell since they serve
only to direct immune effectors to the tumor cell. Selection of
antigen negative variants can occur when targeting non-essential
molecules (Czerniecki et al., 2007; Sampson et al., 2010), but thus
far this has not been the major factor limiting the effectiveness of
immune based therapies (Smith, 2003). Thus, while it is desirable
for immune targets to be involved in tumor growth/survival, this
is not a requirement.
A second area whereby target selection for oncogene-inhibition
differs from immunotherapy relates to the importance of tumor-
speciﬁc mutations. Mutated genes are compelling targets for
oncogene-inhibition since they implicate the target as a “driver” in
oncogenesis, and mutated kinases can be speciﬁcally targeted with
small molecules. For immune based targeting, mutated targets
present both opportunities and challenges. Tumor-speciﬁc muta-
tions are predicted to be more immunogenic than non-mutated
molecules, since immune tolerance to somatically mutated mole-
cules is not induced during normal development. Consistent with
this, early encouraging results have been reported with a vaccine
targeting EGFRvIII, a mutated EGFR in gliomas (Sampson et al.,
2010). But, the corollary is that the number of epitopes generated
by most mutations is small, and the likelihood that any one epi-
topewill be immunogenic is also very small. Becausemostmutated
molecules in cancer reside intracellularly and can only be recog-
nized by MHC restricted T cell receptors, the epitopes that are
“immunogenic” will be so only in the fraction of the population
expressing the appropriate MHC allele. For example, the break-
point regions of PAX3–FKHR (van den Broeke et al., 2006) and
SYS–SSX2 (Worley et al., 2001) are predicted to be immunogenic
inHLA-B7+ individuals,which comprise only approximately 15%
of the population. Immune therapies that target one epitope
present in only a small fraction of the population are difﬁcult to
standardize and translate into off-the-shelf therapies. Thus, very
few tumor-speciﬁc mutations have been targeted successfully via
immunotherapy.
Despite these challenges, the likelihood that immunogenic
epitopes are present in any individual cancer increases with an
www.frontiersin.org January 2012 | Volume 2 | Article 3 | 1
Orentas et al. Immune targets
increase in mutation frequency. Carcinomas are estimated to
carry, on average, 7–10 unique, novel mutations capable of being
recognized by the immune system (Segal et al., 2008). Such
“tumor-speciﬁc” immunogenicity was directly demonstrated in
early studies of carcinogen induced sarcomas wherein tumor-
speciﬁc immunity in individual tumor bearingmicewas not found
in genetically identical littermates bearing tumors of the same his-
tology, presumably due to the presence of unique tumor-speciﬁc
mutations in individual tumors (Wortzel et al., 1983). This con-
cept of “private antigens” provides rationale for patient-speciﬁc
immunotherapies such as whole cell vaccines, and/or broad based
immunomodulators such as anti-CTLA4 or anti-PD1, which can
augment immunity to “personal epitopes” and result in meaning-
ful antitumor effects across populations,albeit todifferent epitopes
in different individuals (Peggs et al., 2006; Ascierto et al., 2010).
A third point to consider when selecting immune based tar-
gets relates to exclusivity of tumor expression. Tumor exclusivity
is desirable but rare, and target expression on some normal tis-
sues is not necessarily a barrier to immune based targeting. Many
successful immune targets display some normal tissue expres-
sion, including cancer–testis antigens that are also expressed on
testicular germ cells, prostate speciﬁc antigen, and prostate acid
phosphatase expressed in normal prostatic tissue, gp100, and
tyrosinase expressed by normal melanocytes, and CD19, CD20,
and CD22 expressed by normal B-cells. Normal tissue expression
does however carry the risk of on-target, off-tumor effects, as evi-
denced by vitiligo following immunotherapy for melanoma due
to damage to normal melanocytes (Turk et al., 2002; Luiten et al.,
2005; Gogas et al., 2006), and loss of normal B-cells when targeting
B-cell antigens (Kochenderfer et al., 2010). High-level expression
can also limit the effectiveness of immunotherapy by inducing
immune tolerance or by competing with the tumor target. More-
over, even limited non-tumor expression on vital organs can lead
to unacceptable toxicity. Thus, optimal immune based targets do
not necessarily require tumor exclusivity, but should have limited
normal tissue expression that does not include cells required for
maintaining vital tissue or organ functions.
Working from these fundamental principles, this manuscript
will discuss candidate targets for immune based therapies of child-
hood cancer, including cell surface antigens suitable for non-MHC
restricted targeting as well as MHC restricted T cell targets.
CELL SURFACE ANTIGENS: NON-MHC RESTRICTED IMMUNE
TARGETS IN PEDIATRIC CANCER
Immune based targeting of tumor cell surface molecules can uti-
lize native antibodies, antibody-derived molecules linked to drugs,
toxins, or radioactive isotopes, bi-speciﬁc antibodies that recruit
effector immune cells (Baeuerle and Reinhardt, 2009), or T or NK
cells genetically engineered to express a receptor that recognizes
the antigen. Recently afﬁnity-matured oligonucleotide structures,
termed aptamers, have been used to target the tumor cell surface
as well (Pastor et al., 2011). Regardless of the approach used, one
compelling feature of targeting cell surface antigens in pediatric
cancers is the lack of MHC restriction, which renders therapies
applicable to all patients expressing the antigen on their tumor
cells, regardless of MHC allele expression.
Historically, monoclonal antibodies, or their derivatives, could
only passively target cell surface antigens, mediating antitumor
effects only as long as the antibody was present. T cell based ther-
apies, in contrast could mediate active immunotherapy, since they
had the potential for in vivo expansion, long-term persistence,
and immune memory. These advantages of T cell based therapies,
however, were offset by limitations posed by MHC restriction,
where any particular antigen could only be targeted in individ-
uals with a particular MHC allele. The development of chimeric
antigen receptors (CARs), which endow T cells with the reactivity
of a monoclonal antibody, combines the beneﬁts of T cell based
therapy but with MHC independence (Figure 1). For these rea-
sons, many are optimistic that CARs will ultimately prove to be
effective, off-the-shelf reagents with broad applicability in can-
cer (Urba and Longo, 2011). The fact that academia can generate
these therapies, without the large scale pharmaceutical investment
required for small molecule oncogene inhibitors, further enhances
the attractiveness of this approach for targeting rare cancers, such
as those occurring in children. For a detailed discussion of the cur-
rent strategies and challenges facing CAR-based immunotherapy,
please see Lee DW et al.,Clinical Cancer Research (In Press). Below
is a summary of cell surface molecules expressed by pediatric can-
cers that are candidates for immune based targeting. Those targets
that are the focus of substantial current research are discussed in
the text, while a more complete listing is provided in Table 1.
CANDIDATE CELL SURFACE IMMUNE TARGETS EXPRESSED
ON HEMATOLOGIC MALIGNANCIES OF CHILDHOOD
CD19
CD19 is an ideal immune target, being universally expressed by
acute lymphoblastic leukemia, the most common malignancy of
children, whereas expression on non-tumor tissues is restricted
to B-cells and their progenitors but not hematopoietic stem cells
(Nadler et al., 1983, 1984). Despite this favorable tissue distri-
bution, early studies with unconjugated anti-CD19 monoclonal
antibodies and anti-CD19 immunotoxins against CD19+ lym-
phomas were ineffective (Stone et al., 1996; Furman et al., 2011;
Schindler et al., 2011). Recently however, a variety of new therapies
targeting CD19 have shown promise. Blinatumomab (anti-CD19
BiTE) is a bi-speciﬁc antibody that binds CD19 and CD3, thus
activating T cells in close proximity to CD19+ lymphoblasts.
This agent showed antitumor activity in adults with B-cell lym-
phoma (Bargou et al., 2008), and in adult ALL patients treated
with minimal residual disease, 16/21 patients had clearance of
leukemia after blinatumomab monotherapy (Topp et al., 2011).
Of four patients who suffered a relapse following blinatumomab,
two were in sanctuary sites (testis, brain), and two relapsed with
CD19− ALL, suggesting that tissue penetration and the devel-
opment of antigen negative variants could pose a challenge for
monotherapy with this agent (Topp et al., 2011). Reversible neu-
rotoxicity was also observed in two patients (Topp et al., 2011). A
Phase II trial enrolling adult patientswith relapsed/refractory adult
ALL with at least 5% bone marrow blasts is currently underway
(NCT01209286), but pediatric studies have not yet been initiated.
Anti-CD19 CAR therapies have also induced robust clinical
responses in CD19 expressing malignancies. Remissions have now
been documented in refractory B-cell lymphoma and CLL after
administration of lymphodepleting chemotherapy followed by
infusion of T cells transduced to express anti-CD19CAR (Kochen-
derfer et al., 2010; Kalos et al., 2011; Porter et al., 2011). These
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FIGURE 1 | Chimeric antigen receptors provide for expanded targeting
opportunities compared toT cell receptors. Chimeric antigen receptors
(CARs) combine a variety of antigen-recognition strategies with the
functionality of theT cell receptor and a co-stimulatory signal (i.e., Signal 2)
and eliminates MHC restriction. This potentially allows for the targeting of any
extracellular moiety such as signaling or cytokine receptors, cell adhesion
molecules, gangliosides, or other proteins communicating with the
extracellular matrix. In contrast, the classic T cell receptor recognizes
processed peptides in the context of MHC providing a strategy for targeting
intracellular, immunogenic antigens.
studies provide proof-of-principle that anti-CD19 CAR thera-
pies can mediate impressive antitumor effects. Yet many questions
remain regarding the optimal methods for generating CAR T cells,
optimal preparative regimens, whether concurrent cytokine ther-
apy improves outcomes and the relative importance of speciﬁc T
cell subsets in mediating antitumor effects. Two pediatric studies
are currently using anti-CD19 CARs to treat ALL (NCT00840853
and NCT01430390). Both administer virus-speciﬁc T cells trans-
duced with the anti-CD19 CAR, an approach that substantially
extends the time it takes to generate the cells, but could trans-
late into improved persistence as demonstrated using GD2–CAR
T cells (Pule et al., 2008). While the elimination of normal B-
cells has been observed in adult CD19 CAR trials similar to
patients who receive the anti-CD20 monoclonal antibody, rit-
uximab, patients tend to tolerate this on-target side effect with
appropriate supportive care. In fact, the constant production of
B-cells by CD19− progenitors may provide chronic, low-level
stimulation to transferred anti-CD19 CAR T cells thereby poten-
tially contributing to persistence and long-term surveillance for
leukemia relapse. It is anticipated that several more trials will open
soon using anti-CD19 CAR T cells to treat pediatric ALL, using
a variety of CAR constructs, T cell populations and treatment
schemas.
CD22
CD22 is also universally expressed on pediatric ALL blasts
and its expression is also restricted to the B-cell compartment
(Campana et al., 1985; Gudowius et al., 2006). Epratuzumab,
an unconjugated anti-CD22 antibody, was not sufﬁcient as a
single agent to achieve clinical responses in pediatric ALL,
but when combined with four-drug re-induction chemother-
apy 9/18 patients achieved a CR with seven of those nine MRD
negative (Raetz et al., 2008). Phase II studies of epratuzumab
alone and in combination with other chemotherapy regimens
and haploidentical NK cell infusions are underway. Because
CD22 is efﬁciently internalized (in contrast to CD19; Chan
et al., 1998) and since internalization is important for the efﬁ-
cacy of immunotoxins, there has also been substantial inter-
est in the development of anti-CD22 immunotoxins. Moxetu-
momab pasudotox, a high-afﬁnity anti-CD22 antibody conju-
gated to pseudomonas exotoxin, has induced complete responses
in 4/17 (24%) patients with refractory and relapsed pediatric
ALL and most patients showed evidence for antitumor activ-
ity with little toxicity (Wayne et al., 2010; NCT00659425). Ino-
tuzumab ozogamycin is another anti-CD22 immunotoxin also
under study in patients 16 years of age and older with ALL and
B-cell lymphoma (NCT01134575). This immunotoxin uses the
same calicheamicin derivative found in Mylotarg (gemtuzumab
ozogamicin).
Combotox, a 1:1 mixture of anti-CD19 and anti-CD22 anti-
bodies conjugated to deglycosylated ricin-A chain has recently
shown hematologic activity in 10/17 children with refractory ALL,
of which three were complete responses (Herrera et al., 2009).
Similarly, hematologic activity was observed in adults with ALL,
although dose limiting capillary leak syndrome was observed
(Schindler et al., 2011). Combotox is currently being investi-
gated in adult ALL to determine the MTD when co-administered
with 3 days of high-dose cytarabine (4 g/m2/day; NCT01408160).
DT2219ARL is another bi-speciﬁc antibody targeting CD19 and
CD22 that is conjugated to diphtheria toxin and is also cur-
rently under study in pediatric ALL (NCT00889408; Vallera et al.,
2009). Finally, anti-CD22 CAR T cell therapy is being actively
pursued with some preclinical activity reported (James et al.,
2008).
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CD20
Rituximab (Rituxan®), an anti-CD20 monoclonal antibody, was
the ﬁrst approved for use in human cancer and remains one of the
most successful immunologics in cancer therapy.Rituximab is now
integrated into standard therapies for B-cell lymphomas (Coifﬁer
et al., 2002; Thomas et al., 2006; Meinhardt et al., 2010; Kumar
et al., 2011), chronic lymphocytic leukemia (Woyach et al., 2011),
post-transplant lymphoproliferative disorder (Evens et al., 2010),
and various autoimmune diseases (Stasi et al., 2001; Leah, 2011).
Despite substantial depletion of normal B-cells following ritux-
imab therapy, immunosuppression has not limited its use and B-
cell numbers return to baseline within 3–6months of completion
of therapy (Thomas et al., 2006; Grifﬁn et al., 2009). Not surpris-
ingly, a variety of anti-CD20 based radioconjugates (Zinzani et al.,
2008; Witzig et al., 2011) and CARs have also been successfully
developed for adult malignancies (Till et al., 2008). In pediatric B-
cell malignancies however, anti-CD20 therapies have had a limited
role since neither ALL nor pediatric B-cell lymphomas commonly
express CD20. (Jeha et al., 2006; Piccaluga et al., 2010) Interest-
ingly though, recent data suggests that CD20 may be upregulated
on ALL blasts after induction chemotherapy or with steroids, pro-
viding rationale for renewed efforts at the immunotherapeutic
targeting of CD20 in pediatric ALL (Gaipa et al., 2005; Dworzak
et al., 2008; NCT01363128; and NCT01279707).
CD52
Alemtuzumab (Campath®) is a humanized monoclonal antibody
to CD52 approved for use in adults with chronic lymphocytic
leukemia. CD52 is expressed on essentially all T cell ALL blasts and
the vast majority of B-cell ALL cases also show high-level CD52
expression (Piccaluga et al., 2010). Despite this, alemtuzumab
as a single agent has limited activity in patients with refractory
pediatric ALL (Angiolillo et al., 2009). Furthermore, CD52 is
widely expressed throughout the hematopoietic system, includ-
ing B-cells, T cells, NK cells, monocytes, macrophages, dendritic
cells (DC), neutrophils, and mast cells. As a result, treatment with
alemtuzumab is myelosuppressive and immunosuppressive (Tang
et al., 1996), which limits enthusiasm for combining it with other
therapies. Nevertheless, trials are underway to explore the efﬁ-
cacy of adding alemtuzumab to intensiﬁcation or clofarabine in
adolescents and adults with ALL (NCT00061945; NCT00983528).
Perhaps the most important role for alemuzumab in pediatric
hematology/oncology is as an adjunct to bone marrow trans-
plantation, where it has been shown to enhance engraftment and
diminish graft-versus-host disease (Flynn and Byrd, 2000; Shah
et al., 2007).
CD30
CD30 is expressed by anaplastic large cell lymphoma (ALCL) and
Reed–Sternberg cells inHodgkin lymphoma (HL; Stein et al., 1985;
Leoncini et al., 1990). A member of the TNF receptor superfamily,
CD30 is also expressed by activated and memory T cells, and acti-
vated B-cells, where it mediates a complex myriad of activation
and regulatory signals via NF-κB (Kennedy et al., 2006; Angiolillo
et al., 2009). Early attempts to treat HL and ALCL with uncon-
jugated anti-CD30 antibodies were largely unsuccessful (Ansell
et al., 2007; Forero-Torres et al., 2009). However, recently, Younes
and colleagues reported impressive results following treatment of
patients with refractory CD30+ lymphomas with brentuximab
vedotin, an anti-CD30 antibody conjugated to the antitubulin
agent monomethyl auristatin E. Brentuximab vedotin engages
CD30 on the Reed–Sternberg cells and is internalized where its
toxin is cleaved, arresting the cell cycle. 36/42 HL patients receiv-
ing brentuximab vedotin had tumor regression, of which 11 had
complete responses while 2/2 additional complete responses were
seen inALCLpatients (Younes et al., 2010). Together, this illustrates
that even in the face of disappointing results with unconjugated
antibodies, improved efﬁcacy can be attained by using antibodies
to direct the delivery of a toxic or cellular payload. To that end,
CARs targeting CD30 are currently under study (NCT01192464;
NCT01316146), but results have not yet been reported.
CANDIDATE CELL SURFACE IMMUNE TARGETS EXPRESSED
ON SOLID TUMORS OF CHILDHOOD
GANGLIOSIDES
GD2’s precise role in cell biology remains unclear, but it appears
to represent a developmental antigen, since it is expressed on mes-
enchymal stem cells derived from bone marrow, adipose, and
umbilical cord blood (Jin et al., 2006). The GD2 ganglioside is
overexpressed on neuroblastoma, melanoma, and some sarcomas
(Schulz et al., 1984;Navid et al., 2010) and recent, deﬁnitive studies
demonstrated that anti-GD2 antibody therapy improves survival
in high-risk neuroblastoma (Yu et al., 2010). GD2 on neuroblas-
toma has also been targeted in clinical trials using ﬁrst generation
CARs with some evidence for clinical activity (Park et al., 2007;
Pule et al., 2008) and persistence (Louis et al., 2011). More recent
preclinical studies demonstrated improved efﬁcacy of GD2–CARs
with the addition of chemokine receptors that improve homing to
tumor (Craddock et al., 2010). In both monoclonal antibody and
anti-GD2 CAR trials, targeting GD2 has been deemed safe.
Other gangliosides also represent attractive immune targets
in pediatric oncology. GD3 is a disialoganglioside that is not
expressed on normal tissues, but can be found on the surface of
melanoma, soft-tissue sarcoma, and tumors of neuroectodermal
origin (Hamilton et al., 1993). High tumor growth rates corre-
late with high-levels of GD3 synthesis (Ravindranath et al., 2007).
First and second generation anti-GD3 CARs induce anti-tumor
effects in animal models of melanoma (Lo et al., 2010). Finally,
N -glycoylated gangliosides incorporate N -glycoyl, a molecule not
produced by human cells but thought to be derived from diet, then
incorporated into the tumor cell surface as a result of a response
to hypoxia (Scursoni et al., 2010; Bernstein, 2011). N -glycoyl-
GM3 was recently described to be present on the surface of Wilms’
tumor, neuroblastoma, and Ewing sarcoma (Mulens et al., 2010).
Since N -glycoylated gangliosides are not expressed by any normal
tissue, thesemoleculesmay provide an ideal target for toxin and/or
CAR-based immunotherapies.
GROWTH FACTOR RECEPTORS AND ONCOGENES
IL-13Rα2
IL-13 is a Th2 cytokine that can bind to the low afﬁnity IL-
13Rα1 receptor, that signals in conjunction with IL-4Rα, or a
high-afﬁnity IL-13Rα2 receptor that binds and internalizes the
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cytokine on its own (Wynn, 2003). The low afﬁnity receptor com-
plex activates Jak–STAT pathways of signal transduction while the
high-afﬁnity receptor, the normal expression of which is limited
to lung epithelial cells and ﬁbroblasts at low-levels that increase
with injury (Kawakami et al., 2006; Hecker et al., 2010), signals
through the AP-1 transcription factor and induces production of
TGFβ (Fichtner-Feigl et al., 2006). A wide array of tumors express
IL-13Rα2, including 80% of glioblastomas, most diffuse intrin-
sic pontine gliomas as well as melanoma and renal cell, prostate,
ovarian, and pancreatic carcinomas (Kioi et al., 2008; Takenouchi
et al., 2011). Preferential expression on tumor cells has led to tar-
geting by a variety of immunotherapeutics, including a fusion
protein between IL-13 and pseudomonas exotoxin (cintredekin
besudotox), which failed to show enhanced efﬁcacy compared
to a standard therapy when regionally delivered in glioblastoma
multiforme (Kioi et al., 2008; Kunwar et al., 2010), but stud-
ies are continuing in pediatric diffuse intrinsic pontine glioma
(NCT0088006). Jensen and colleagues reported antitumor effects
in a glioblastoma xenograftmodel of CAR transduced T cells using
an afﬁnity enhanced IL-13 instead of antibody-based motifs to
direct T cell targeting (Oshima et al., 2000; Kahlon et al., 2004).
VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2
VEGFR2 (Flk-1/KDR), a transmembrane tyrosine kinase, is the
primary cellular receptor for vascular endothelial growth fac-
tor (VEGF). VEGFR2 is unique among tumor targets since it is
expressed on tumor vasculature instead of the tumor itself, as well
as on regulatory T cells (Brown et al., 1993). Mouse models of
malignancy originally identiﬁed CD8+ T cell clones speciﬁc for
VEGFR2-derived peptides that could inhibit tumor angiogenesis
and growth (Dong et al., 2006; Suzuki et al., 2010). VEGFR2-
speciﬁc CARs have demonstrated antitumor activity in murine
models (Chinnasamy et al., 2010) and a clinical trial is currently
underway (NCT01218867). While the potential for targeting both
T regulatory cells and tumor vasculature is compelling, caution
in immune based targeting of VEGFR2 should be exercised as it
is expressed at lower levels on normal blood vessels and other
tissues and is upregulated on blood vessels during wound heal-
ing (Chinnasamy et al., 2010; Edelbauer et al., 2010). In addition,
elimination of T regulatory cells may lead to autoimmunity.
HER2/Neu (ERBB2)
Monoclonal antibody-based targeting of the ampliﬁed human
epidermal growth factor receptor 2 (HER2/Neu) oncogene with
trastuzumab (Herceptin®), in breast cancer has been a major suc-
cess of tumor immunotherapy (Gonzalez-Angulo et al., 2006).
Although not clearly credentialed as an oncogene in pediatric can-
cers (Gilbertson, 2005), Her2/Neu is expressed on Wilms’ tumor,
medulloblastoma, and osteosarcoma but at levels that are not
sufﬁcient for antitumor effects using trastuzumab (Ragab et al.,
2010). However, investigators have demonstrated activity of anti-
Her2/Neu CARs created using the trastuzumab binding motif
(Ahmed et al., 2009; Zhao et al., 2009). Thus the threshold of
expression required for targeting cells with CARs may be lower
than that for monoclonal antibodies. Unfortunately, the ﬁrst clin-
ical trial of an anti-Her2/Neu CAR in adult cancer was associated
with a fatal adverse event (Morgan et al., 2010), likely related to a
combination of high T cell dose and low-level Her2/Neu expres-
sion in the lung, which resulted in massive cytokine release. This
event does not necessarily preclude future immune targeting of
ERBB2, as lower cell doses or different combinations of signal-
ing motifs may ultimately prove to be safe. In fact, a phase I
trial of anti-Her2/Neu CAR therapy in osteosarcoma using a cau-
tious dose escalation scheme is currently underway and substantial
toxicity has not been observed so far (NCT00902044).
ANAPLASTIC LYMPHOMA KINASE
Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in
the insulin receptor superfamily, was ﬁrst discovered as a part-
ner with nucleophosmin in the oncogenic fusion protein found in
ALCLs (Webb et al., 2009). During neuronal development, ALK
is expressed as a transmembrane protein, then downregulated
soon after birth. In mature animals, ALK shows restricted CNS
expression, limited to rare neurons, pericytes, and endothelial cells
(Pulford et al., 1997; Falini et al., 1999). The true ligand for ALK is
still in question as some studies implicate pleiotrophin/midkine,
while others do not (Moog-Lutz et al., 2005; Wellstein and Toret-
sky, 2011). In either case, a double knockdown of ALK and
pleiotrophin blocks glioma tumorigenesis. (Grzelinski et al., 2009)
Full-length, cell surface ALK expression is observed in a wide array
of tumors including lung cancer,neuroblastoma,neuroectodermal
tumors, glioblastoma, rhabdomyosarcoma, and melanoma (Webb
et al., 2009) and recently ALK was identiﬁed as an oncogene in
both familial and sporadic neuroblastoma (George et al., 2008;
Mosse et al., 2008). Thus, ALK represents a promising target for
both oncogene-inhibition and immunotherapy.
EGFRvIII
A mutant, constitutively activated form of the epidermal growth
factor receptor, EGFRvIII, is overexpressed on the surface of
approximately 20% of adult and pediatric gliomas (Heimberger
et al., 2005; Bax et al., 2009). EGFRvIII has been targeted with T
cell based immunotherapy as a vaccine (Sampson et al., 2010), and
in addition, CAR vectors targeting EGFRvIII have been produced
and validated in vitro, and clinical trials are awaited (Bullain et al.,
2009; Ohno et al., 2010). Like ALK, the potential role of EGFRvIII
in the growth/survival of these tumors makes it a promising target
for both oncogene-inhibition and immunotherapy.
FIBROBLAST GROWTH FACTOR RECEPTOR 4
There are over 20 known ﬁbroblast growth factors, the activ-
ity of which are mediated by four distinct receptors. Fibroblast
growth factors play myriad roles in cell signaling, growth and
differentiation, and mutations or alterations in this system have
been described in a number of malignancies (Olsen et al., 2003;
Wesche et al., 2011). Antibodies to ﬁbroblast growth factor recep-
tor 3 (FGFR3) are currently undergoing trials inmultiplemyeloma
(NCT00866138). FGFR4 is a new target identiﬁed in pediatric
solid tumors that is overexpressed by nearly all rhabdomyosarco-
mas with activating point-mutations observed in more aggressive
disease (Taylor et al., 2009; Paulson et al., 2011) and with limited
expression on normal myocytes. Thus, it also serves as a candidate
target for both oncogene-inhibition and immunotherapy.
www.frontiersin.org January 2012 | Volume 2 | Article 3 | 7
Orentas et al. Immune targets
OTHER CELL SURFACE MOLECULES
4IgB7-H3
Most adhesion receptors are broadly expressed, but some such as
B7-H3 are expressed in amore restricted fashion,and thus offer the
potential for immune targeting in cancer. B7-H3 has two isoforms;
the 2Ig-B7-H3 isoform is expressed on mature DC and a num-
ber of carcinoma cell lines (Zhang et al., 2005) but has not been
reported on pediatric tumors. However, the 4Ig-B7-H3 isoform is
expressed on neuroblastoma (Castriconi et al., 2004) and has been
reported to be the target of 8H9 (Xu et al., 2009), a monoclonal
antibody which binds to a wide array of pediatric tumors, includ-
ing sarcomas and most brain tumors (Modak et al., 2001, 2002).
Masking of 4Ig-B7-H3 enhances NK cell lysis of neuroblastoma
cell lines, suggesting that it may negatively regulate NK signaling
(Castriconi et al., 2004). Clinical studies are currently under-
way using radioconjugated 8H9 for treatment of intraperitoneal
desmoplastic small round cell tumor (NCT01099644) aswell as for
leptomeningeal spread of 8H9 binding tumors (NCT00089245).
Due to concerns regarding hepatic expression of the 8H9 binding
antigen, systemic administration of this monoclonal antibody has
not been pursued. It remains unclear whether hepatic expression
of 4IgB7-H3 will preclude systemic targeting of this antigen.
GLYPICANS
Glypican-3 is a cell surface peptidoglycan found on the sur-
face of hepatocellular carcinoma and melanoma, and glypican-3
mRNA has been demonstrated on embryonal tumors including
neuroblastoma and Wilms’ tumor (Saikali and Sinnett, 2000;
Nakatsura et al., 2004). Recently, a homologous molecule,
glypican-5 was demonstrated to be ampliﬁed in rhabdomyosar-
coma and to play a role in growth/survival of this tumor
(Williamson et al., 2007). Thus, at least two glypican family of
molecules represent potential targets in embryonal tumors.
ALPHA-FOLATE RECEPTOR
A humanized antibody speciﬁc for alpha-folate receptor (FOLR1),
farletuzumab, is currently in clinical trials for patientswith ovarian
carcinoma (Konner et al., 2010). The expression of this transmem-
brane folate receptor in normal tissues is limited to the luminal side
of epithelium and therefore is not accessible to the vascular sys-
tem and would not be targeted by monoclonal antibody therapies
(Garin-Chesa et al., 1993; Ross et al., 1994). Analyses contained
within the public tissue expression database1document overex-
1http://home.ccr.cancer.gov/oncology/oncogenomics/
Table 2 | Non-CTA, MHC restricted immune targets expressed in pediatric cancer.
Class/target Expression Notes References
DIFFERENTIATIONANTIGENS
Proteinase-3 (PR-3) AML (M2, M3>M4>M1) PR-1 is a PR-3 derived peptide that has
elicited immune responses in clinical trials




≈70% AML Limited data on pediatric versus adult
leukemias




Ewing sarcoma Data too limited to denote approximate
percentage
Hu-Lieskovan et al. (2005), Hubert et al.
(1999)
ONCOGENES
Flt3–ITD ≈25% Pediatric AML HLA-A1 epitope identiﬁed Brown et al. (2004)
Her2/Neu ≈60% Osteosarcoma*
≈40% Medulloblastoma
Gilbertson (2005), Ahmed et al. (2009), Gor-
lick et al. (1999), Hughes et al. (2004),
Ahmed et al. (2007), Tong et al. (2004)
WT1 ≈70–80% AML HLA-A1, A24, DP5, DR4 epitopes
identiﬁed
Inoue et al. (1997), Rosenfeld et al. (2003),
Ohta et al. (2009), Nakatsuka et al. (2006)≈60–80% ALL
≈100% Rhabdomyosarcoma
≈50% ESFT
Survivin All tumors Fratricide reported by high-afﬁnity
survivin-speciﬁc CTLs due toT cell
survivin expression
Leisegang et al. (2010), Coughlin et al.
(2004, 2006), Rapoport et al. (2011)
Telomerase (hTERT) All tumors Rapoport et al. (2011)
BCR–ABL (p210) 100% CML HLA-A2, B8, DR4, DR9 epitopes identiﬁed Yotnda et al. (1998a)
PAX3–FKHR ≈90% Alveolar
rhabdomyosarcoma
HLA-B7 epitope identiﬁed van den Broeke et al. (2006)
SYT–SSX1, SSX2 100% Synovial sarcoma HLA-B7 epitope identiﬁed Worley et al. (2001)
ETV6–AML1 ≈25% ALL HLA-A2, HLA-DP5, HLA-DP17 epitopes
identiﬁed
Yotnda et al. (1998b)
PML–RARα 100% M3-AML HLA-DR11 epitope identiﬁed Gambacorti-Passerini et al. (1993)
*Expression in osteosarcoma is not associated with ampliﬁcation as observed in Her2/Neu expressing breast carcinomas.
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pression in some pediatric tumors as well, including osteosar-
coma and Ewing’s sarcoma. CAR-based cell therapies targeting
FOLR1 are underway and could potentially be extended to FOLR1
pediatric tumors (Kershaw et al., 2006).
MHC RESTRICTED IMMUNE TARGETS IN PEDIATRIC CANCER
WILMS’ TUMOR ANTIGEN
Wilms’ tumor antigen (WT1) is expressed by several pediatric
tumors, and appears to be immunogenic (Cheever et al., 2009).
Some concerns remain regarding expression on hematopoietic
stem cells, renal podocytes, and potentially other cycling pop-
ulations, but the community remains optimistic that WT1 may
prove to be an effective tumor antigen, as it was ranked the most
promising of all tumor antigens by the NCI (Cheever et al., 2009).
Several small, non-randomized studies have demonstrated WT1
speciﬁc immunity following peptide based vaccination and in
some cases this was associated with evidence for anti-leukemic
activity. An ongoing vaccine trial is underway for patients with
recurrent leukemias and lymphoma at theNCI PediatricOncology
Branch (NCT00923910).
SURVIVIN
Survivin is an anti-apoptotic molecule that is overexpressed in
most tumors, but also has widespread low-level expression in
normal tissues. Survivin-speciﬁc T cells have been isolated from
patients with cancer, including neuroblastoma, and some groups
have demonstrated that survivin-speciﬁc T cells can mediate
tumor lysis (Cheever et al., 2009). Based upon these results, sev-
eral investigators sought to develop high-afﬁnity survivin-speciﬁc
T cells. Remarkably, such cells are able to lyse nearly all tumors but
alsomediate fratricide of normal T cells due to survivin expression
following activation (Leisegang et al., 2010). Thus, normal tissue
expression of survivin appears likely to limit the effectiveness of
immunotherapies targeting this antigen and similar limitations
could apply to other broadly expressed tumor antigens.
Several other non-cancer testis antigens that are candidate
MHC restricted T cell targets expressed in pediatric tumors are
shown in Table 2.
CANCER–TESTIS ANTIGENS
Cancer testis antigens [also referred to as cancer germline genes
(CGG)] are expressed in a wide array of cancers, with normal
tissue expression limited to testicular germ cells and placental tro-
phoblasts (see detailed reviews Fratta et al., 2011 and detailed
listing of the genes at http://www.cta.lncc.br). The ﬁrst tumor
antigen identiﬁed, MAGE-A1, is a prototype and since its dis-
covery the family has expanded to comprise 70 families with over
140 antigens. Over half of the CTAs are encoded by the X chro-
mosome (X-CTA) and it is estimated that approximately 10% of
the X chromosome encodes for these molecules. Expression is
regulated in large part by epigenetic factors, although the BORIS
transcription factor has also been shown to be a potent inducer
of their expression (Fratta et al., 2011). The biologic function of
CTAs has remained elusive and their scientiﬁc interest has been
primarily based upon their inherent immunogenicity and their
restricted tissue expression, which has made them compelling
immune targets.
The CTA family ofﬁcially encompasses a vast number of mole-
cules (Almeida et al., 2009), but a much smaller number have been
demonstrated to be immunogenic and thus are truly promising
targets for immunotherapies (detailed in http://www.cancer
immunity.org/peptidedatabase/tumorspeciﬁc.htm). Furthermore,
analysis of CTAs in pediatric tumors has been limited (Liu et al.,
2000; Zendman et al., 2002; Foell et al., 2008; Jacobs et al., 2008;
Oba-Shinjo et al., 2008; Grau et al., 2009; Pollack et al., 2011).
A summary of the studies reporting CTAs in pediatric tumors is
shown in Table 3, but several caveats should be emphasized. First,
most studies involve limited numbers of tumors, which are not
adequate to reliably deﬁne the percent of tumors of any speciﬁc
histology expressing CTAs, and most studies have not been con-
ﬁrmed. Thus, the prevalence of expression listed for any histology
must be considered an approximation at best.
Second, whereas NY-ESO-1 and PRAME each represent one
gene, the rest of the CTAs shown in Table 3 represent gene fami-
lies, for which expression is likely to vary across the speciﬁc genes
Table 3 | Cancer testis antigens in pediatric tumors.










Jacobs et al. (2007), Rob-
bins et al. (2011), Segal
et al. (2005), Jungbluth
et al. (2001)





≈60% pediatric acute myeloid
leukemia
Segal et al. (2005),Vulcani-
Freitas et al. (2011), Toledo
et al. (2011), Steinbach
et al. (2006), Steinbach
et al. (2002), Spanaki et al.
(2007), Boon et al. (2003),
Oberthuer et al. (2004)








Jacobs et al. (2007),
Kasuga et al. (2008)






Steinbach et al. (2006),
Kasuga et al. (2008)
XAGE-1 ≈40–90% Ewing sarcoma Liu et al. (2000), Zendman
et al. (2002)
∞Documentation of protein expression is limited toNY-ESO-1 in synovial sarcoma,
and MAGE-A1 and A4 in limited numbers of pediatric solid tumors (Jacobs et al.,
2007) and brain tumors (Jacobs et al., 2008).
§MAGE-A1 expression is absent in synovial sarcoma by immunohistochemistry
(Jungbluth et al., 2001).
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within that family. For example,within the MAGEA family at least
eight different immunogenic genes have been identiﬁed (A1-4, 6,
9, 10, and 12). Given that targeted immunotherapy trials typically
focus on one antigen, the percent of tumors that could be targeted
with any given vaccine will be limited to those tumors express-
ing that speciﬁc gene. Third, very few studies have incorporated
immunohistochemistry or other approaches to conﬁrm protein
expression of CTAs in pediatric tumors. In the few that have,
some have reported that mRNA expression correlated with pro-
tein expression (Jacobs et al., 2007), while others have noted that
mRNA positivity is associated with patchy or very weak immuno-
histochemical staining (Oba-Shinjo et al., 2008). Together, one can
conclude that CTAs are likely to be expressed in a sizable percent-
age of childhood cancers, but substantially more work is needed to
accurately deﬁne the prevalence of CTA protein expression among
pediatric histologies, to better characterize the intensity, distribu-
tion, and extent of homogeneity of CTA expressionwithin tumors.
Clariﬁcation of these issues is needed before one can accurately
predict whether targeting CTAs for immunotherapy of pediatric
cancer is likely to be effective.
One tumor where robust CTA protein expression has been
clearly documented is synovial sarcoma. NY-ESO-1 expression is
seen in approximately 70% of synovial sarcomas and is character-
ized by diffuse, intense protein expression. Furthermore, prelim-
inary results demonstrate that meaningful antitumor effects can
result from targeting NY-ESO-1 in these tumors, most recently
using adoptive transfer of T cells genetically engineered to express
a high-afﬁnity NY-ESO-1 peptide speciﬁc T cell receptor (Robbins
et al., 2011). Despite these exciting results, challenges in translat-
ing this therapy on a larger scale epitomize the challenges unique
to T cell based immunotherapies. The TCR used in this therapy
targets an HLA-A2 restricted peptide, and approximately 40% of
the Caucasian population expresses HLA-A2,while lesser percent-
ages are found in individuals of Asian and African descent. There
are approximately 800 new diagnoses of synovial sarcoma each
year, of which approximately 200 small tumors (<5 cm) have an
excellent prognosis with surgery alone2. Thus, fewer than 200 new
cases of synovial sarcoma per year could beneﬁt from this excit-
ing emerging therapy. Given the rarity of this disease, it is easy to
understandwhy executing trials and standardizingMHCrestricted
T cell based therapies for rare cancers is challenging.
FERTILE GROUND FOR NEW CANCER IMMUNOTHERAPEUTICS
We have discussed the major, current attractive targets for
immunotherapy in pediatric cancer taking into consideration
expression on normal or vital tissues. While much progress has
been made in pediatric oncology, some subgroups, such as those
with metastatic sarcomas and brain tumors, have not seen major
improvement in survival over the past few decades despite inten-
sifying chemotherapies. The long-term beneﬁt of monoclonal
antibody therapy has yet to be proven and none except anti-GD2
havebecome standard therapy inpediatric oncology. In addition to
further developing monoclonal antibody therapy, the ﬁeld is mov-
ing to use the target cell speciﬁcity of antibody or antibody-like
molecules as a means to deliver toxins or immune effector cells to
the tumor. Advances in small molecule technology, production of
new forms of antibody, and innovations in cell production tech-
niques are responsible for recent exciting results, albeit in small
numbers of patients, mostly limited to adult oncology. Still, these
techniques are just now becoming applicable to the clinic and are
likely to be a fertile arena for clinical progress in pediatric oncology
for the next decade.
2http://sarcomahelp.org/learning_center/synovial_sarcoma.html
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